Please login to the form below

Not currently logged in
Email:
Password:

Vidaza

This page shows the latest Vidaza news and features for those working in and with pharma, biotech and healthcare.

BMS’ oral maintenance therapy boosts survival in AML patients

BMS’ oral maintenance therapy boosts survival in AML patients

CC-486 is an oral version of Celgene’s already-marketed chemotherapy Vidaza (azacitidine), which is administered intravenously – it had been a top-selling product for the company, before being hit ... Vidaza brought in over $600m a year at its peak,

Latest news

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    Meanwhile, BeiGene entered into a strategic global collaboration with Celgene in 2017, gaining the rights to Celgene’s Abraxane Revlimid and Vidaza in China, while Celgene gained an option to market

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics